Prevalence of high fasting plasma glucose and risk of developing end-stage renal disease in screened subjects in Okinawa, Japan

Clinical and Experimental Nephrology

Volumn 8, Issue 3, 2004, Pages 250-256

  Iseki, Kunitoshi ^a   Ikemiya, Yoshiharu ^b   Kinjo, Kozen ^b   Iseki, Chiho ^a   Takishita, Shuichi ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b Okinawa Gen Hlth Maintenance A   (Japan)

Author keywords

Diabetes mellitus; End stage renal disease; Fasting plasma glucose; Screening

Indexed keywords

GLUCOSE;

ADULT; ARTICLE; DIABETES MELLITUS; DIALYSIS; DIET RESTRICTION; FEMALE; GLUCOSE ASSAY; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; INCIDENCE; JAPAN; KIDNEY FAILURE; MALE; MASS SCREENING; PREVALENCE; PROTEINURIA; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; DISEASE PROGRESSION; FASTING; FEMALE; HUMANS; HYPERGLYCEMIA; JAPAN; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MASS SCREENING; MIDDLE AGED; PROTEINURIA; REGISTRIES; RENAL DIALYSIS; RISK FACTORS; SEX FACTORS;

EID: 7044284681     PISSN: 13421751     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10157-004-0293-z     Document Type: Article

References (26)

1. Nakai S, Shinzato T, Sanaka T, Kikuchi K, Kitaoka T, Shinoda T, et al. The current state of chronic dialysis treatment in Japan (as of December 31, 2000). J Jpn Soc Dial Ther 2002;35:1155-84.
2. US Renal Data System: excerpts from the USRDS 2001 Annual Data Report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 2001;38(Suppl 3):S1-248.
3. Schena FP. Epidemiology of end-stage renal disease: international comparisons of renal replacement therapy. Kidney Int 2000;57(Suppl 74):S39-45.
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.
5. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
6. Humphrey LL, Ballard DJ, Frohnert PP, Chu CP, O'Fallon WM, Palumbo PJ. Chronic renal failure in non-insulin-dependent diabetes mellitus. A population-based study in Rochester, Minnesota. Ann Intern Med 1989;111:788-96.
7. Iseki K, Iseki C, Ikemiya Y, Fukiyama K. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int 1996;49:800-5.
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998:352:837-53.
9. US Renal Data System: excerpts from the USRDS 2002 Annual Data Report: atlas of end-stage renal disease in the United States. Am J Kidney Dis 2003;41(Suppl 2):S1-260.
10. Iseki K. The Okinawa screening program. J Am Soc Nephrol 2003;14(Suppl 2):S127-30.
11. Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 2003;41:1341-5.
12. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
13. Iseki K, Tozawa M, Iseki C, Takishita S, Ogawa Y. Demographic trends in the Okinawa Dialysis Study (OKIDS) registry (1971-2000). Kidney Int 2002;61:668-75.
14. Iseki K, Kawazoe N, Osawa A, Fukiyama K. Survival analysis of dialysis patients in Okinawa, Japan (1971-1990). Kidney Int 1993;43:404-9.
15. Sunagawa H, Iseki K, Nishime K, Uehara H, Toma S, Kinjo K, et al. Epidemiologie analysis of diabetic patients on chronic dialysis. Nephron 1996;74:361-6.
16. Iseki K, Miyasato F, Oura T, Uehara H, Nishime K, Fukiyama K. An epidemiologic analysis of end-stage lupus nephritis. Am J Kidney Dis 1994;23:547-54.
17. Iseki K, for the Okinawa Dialysis Study (OKIDS) Group. Analysis of referral pattern and survival in chronic dialysis patients in Okinawa, Japan (1993-1997). Clin Exp Nephrol 2002;6:43-8.
18. Jungers P, Zingraff J, Albouze G, Chauveau P, Page B, Hannedouche T, et al. Late referral to maintenance dialysis: detrimental consequences. Nephrol Dial Transplant 1993;8:1089-93.
19. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 years before clinical diagnosis. Diabetes Care 1992;15:815-19.
20. Hasslacher C, Ritz E, Wahl P, Michael C. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant 1986;4:859-63.
21. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of develoing end-stage renal disease. Kidney Int 2003;63:1468-74.
22. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary ablumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002;106:1777-82.
23. Health and Welfare Statistics Association. Health services in Japan (Kokumin Eisei no Doko). Indices of Health and Welfare (Kosei no Shihyo) 1998;45:102.
24. Iseki K, Oshiro S, Tozawa M, Ikemiya Y, Fukiyama K, Takishita S. Prevalence and correlates of diabetes mellitus in a screened cohort in Okinawa, Japan. Hypertens Res 2002;25:185-90.
25. Grenfell A, Watkins PJ. Clinical diabetic nephropathy: natural history and complications. Clin Endocrinol Metabol 1986;15:783-5.
26. Gambara V, Mecca G, Remuzzi G, Bertani T. Heterogenous nature of renal lesions in type II diabetes. J Am Soc Nephrol 1993;3:1458-66.